Leha, Andreas

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"],["dc.bibliographiccitation.lastpage","7"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Koch, Jan C."],["dc.contributor.author","Statland, Jeffrey M."],["dc.contributor.author","Hussain, Sumaira"],["dc.contributor.author","Hennecke, Christiane"],["dc.contributor.author","Wuu, Joanne"],["dc.contributor.author","Langbein, Thomas"],["dc.contributor.author","Ahmed, Raees"],["dc.contributor.author","Günther, René"],["dc.contributor.author","Ilse, Benjamin"],["dc.contributor.author","Kassubek, Jan"],["dc.contributor.author","Kollewe, Katja"],["dc.contributor.author","Kuttler, Josua"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Lengenfeld, Teresa"],["dc.contributor.author","Meyer, Thomas"],["dc.contributor.author","Neuwirth, Christoph"],["dc.contributor.author","Tostmann, Ralf"],["dc.contributor.author","Benatar, Michael"],["dc.date.accessioned","2021-04-14T08:30:11Z"],["dc.date.available","2021-04-14T08:30:11Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1080/21678421.2021.1879866"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83141"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","2167-9223"],["dc.relation.issn","2167-8421"],["dc.title","Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","104677"],["dc.bibliographiccitation.journal","Neurobiology of Disease"],["dc.bibliographiccitation.volume","134"],["dc.contributor.author","Maass, Fabian"],["dc.contributor.author","Michalke, Bernhard"],["dc.contributor.author","Willkommen, Desiree"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Schulte, Claudia"],["dc.contributor.author","Tönges, Lars"],["dc.contributor.author","Mollenhauer, Brit"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Rückamp, Daniel"],["dc.contributor.author","Börger, Matthias"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Lingor, Paul"],["dc.date.accessioned","2020-12-10T15:20:25Z"],["dc.date.available","2020-12-10T15:20:25Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.nbd.2019.104677"],["dc.identifier.issn","0969-9961"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72661"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","342"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Neurochemistry"],["dc.bibliographiccitation.lastpage","351"],["dc.bibliographiccitation.volume","145"],["dc.contributor.author","Maass, Fabian"],["dc.contributor.author","Michalke, Bernhard"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Boerger, Matthias"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Koch, Jan-Christoph"],["dc.contributor.author","Tönges, Lars"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Lingor, Paul"],["dc.date.accessioned","2018-04-23T11:46:57Z"],["dc.date.available","2018-04-23T11:46:57Z"],["dc.date.issued","2018"],["dc.description.abstract","The diagnosis of Parkinson's disease (PD) still lacks objective diagnostic markers independent of clinical criteria. Cerebrospinal fluid (CSF) samples from 36 PD and 42 age‐matched control patients were subjected to inductively coupled plasma‐sector field mass spectrometry and a total of 28 different elements were quantified. Different machine learning algorithms were applied to the dataset to identify a discriminating set of elements yielding a novel biomarker signature. Using 19 stably detected elements, the extreme gradient tree boosting model showed the best performance in the discrimination of PD and control patients with high specificity and sensitivity (78.6% and 83.3%, respectively), re‐classifying the training data to 100%. The 10 times 10‐fold cross‐validation yielded a good area under the receiver operating characteristic curve of 0.83. Arsenic, magnesium, and selenium all showed significantly higher mean CSF levels in the PD group compared to the control group (p = 0.01, p = 0.04, and p = 0.03). Reducing the number of elements to a discriminating minimum, we identified an elemental cluster (Se, Fe, As, Ni, Mg, Sr), which most importantly contributed to the sample discrimination. Selenium was identified as the element with the highest impact within this cluster directly followed by iron. After prospective validation, this elemental fingerprint in the CSF could have the potential to be used as independent biomarker for the diagnosis of PD. Next to their value as a biomarker, these data also argue for a prominent role of these highly discriminating six elements in the pathogenesis of PD."],["dc.identifier.doi","10.1111/jnc.14316"],["dc.identifier.gro","3142063"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13277"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","0022-3042"],["dc.title","Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","293"],["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Weber, Markus"],["dc.contributor.author","Camu, William"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Neuwirth, Christoph"],["dc.contributor.author","Günther, René"],["dc.contributor.author","Benatar, Michael"],["dc.contributor.author","Kuzma-Kozakiewicz, Magdalena"],["dc.contributor.author","Bidner, Helen"],["dc.contributor.author","Blankenstein, Christiane"],["dc.contributor.author","Frontini, Roberto"],["dc.contributor.author","Ludolph, Albert"],["dc.contributor.author","Koch, Jan C."],["dc.date.accessioned","2019-07-09T11:51:01Z"],["dc.date.available","2019-07-09T11:51:01Z"],["dc.date.issued","2019"],["dc.description.abstract","Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of vasospasm in patients with subarachnoid hemorrhage with a favorable safety profile. Here we describe a clinical trial protocol to repurpose fasudil as a disease-modifying therapy for ALS patients. Methods: ROCK-ALS is a multicenter, double-blind, randomized, placebo-controlled phase IIa trial of fasudil in ALS patients (EudraCT: 2017-003676-31, NCT: 03792490). Safety and tolerability are the primary endpoints. Efficacy is a secondary endpoint and will be assessed by the change in ALSFRS-R, ALSAQ-5, slow vital capacity (SVC), ECAS, and the motor unit number index (MUNIX), as well as survival. Efficacy measures will be assessed before (baseline) and immediately after the infusion therapy as well as on days 90 and 180. Patients will receive a daily dose of either 30 or 60 mg fasudil, or placebo in two intravenous applications for a total of 20 days. Regular assessments of safety will be performed throughout the treatment period, and in the follow-up period until day 180. Additionally, we will collect biological fluids to assess target engagement and evaluate potential biomarkers for disease progression. A total of 120 patients with probable or definite ALS (revised El Escorial criteria) and within 6-18 months of the onset of weakness shall be included in 16 centers in Germany, Switzerland and France. Results and conclusions: The ROCK-ALS trial is a phase IIa trial to evaluate the ROCK-inhibitor fasudil in early-stage ALS-patients that started patient recruitment in 2019."],["dc.identifier.doi","10.3389/fneur.2019.00293"],["dc.identifier.pmid","30972018"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59859"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3"],["dc.bibliographiccitation.journal","Parkinsonism & Related Disorders"],["dc.bibliographiccitation.lastpage","9"],["dc.bibliographiccitation.volume","63"],["dc.contributor.author","Boerger, Matthias"],["dc.contributor.author","Funke, Sebastian"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Roser, Anna-Elisa"],["dc.contributor.author","Wuestemann, Ann-Katrin"],["dc.contributor.author","Maass, Fabian"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Grus, Franz"],["dc.contributor.author","Lingor, Paul"],["dc.date.accessioned","2020-12-10T15:20:41Z"],["dc.date.available","2020-12-10T15:20:41Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.parkreldis.2019.03.001"],["dc.identifier.issn","1353-8020"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72763"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Proteomic analysis of tear fluid reveals disease-specific patterns in patients with Parkinson's disease – A pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Maass, Fabian"],["dc.contributor.author","Rikker, Sebastian"],["dc.contributor.author","Dambeck, Vivian"],["dc.contributor.author","Warth, Carmina"],["dc.contributor.author","Tatenhorst, Lars"],["dc.contributor.author","Csoti, Ilona"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Lingor, Paul"],["dc.date.accessioned","2021-04-14T08:25:46Z"],["dc.date.available","2021-04-14T08:25:46Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1038/s41598-020-65503-1"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17459"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81725"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2045-2322"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]